The adjuvanted, broad-spectrum influenza vaccine FLU-v was found to be immunogenic and merits phase 3 development to explore efficacy.
Researchers determined the risk for Guillain-Barré Syndrome following seasonal influenza vaccination in a real-world study.
Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Implementation of an influenza immunization program increased vaccinations rates from 44% to 57% the following year.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
The FDA has approved Fluad Quadrivalent for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.
The CDC continues to recommend influenza vaccination as the best method of protection while the viruses are circulating in the community.
Black people who are HIV-positive may have a decreased ratio of influenza-specific IgG vs IgM after influenza vaccination.
A double-dose of inactivated influenza vaccine may not increase the immunogenicity of the vaccine among pregnant women with HIV.
The FDA has approved influenza A [H5N1] monovalent vaccine for active immunization for the prevention of disease in patients 6 months of age and older at increased risk of exposure to the influenza A H5N1 virus subtype contained in the vaccine.
Many US adults are misinformed about the influenza virus and the importance of flu vaccination.
Primary care patients with influenza-like illness recovered 1 day sooner on average when treated with oseltamivir compared with those receiving usual care only.
Vaxart announced positive topline data from a phase 2 study evaluating the H1 influenza oral tablet vaccine, VXA-A1.1, for the prevention of influenza disease.
Compared with a standard-dose influenza vaccine, several enhanced influenza vaccines improved humoral and cell-mediated immune responses in older adults.
The Food and Drug Administration has granted Fast Track designation to NanoFlu (Novavax) for seasonal influenza vaccination in adults ≥65 years.
Flu cases and flu-related hospitalizations have risen sharply since October, with at least 6.4 million reported cases and 55,000 hospitalizations.
A new vaccine for the avian influenza A(H5N1) was shown to be safe and immunogenic.